Ghent University Hospital
Ghent, 9000, Belgium
NCT Number: NCT06218277
The investigators want to investigate the clinical impact of early antimicrobial susceptibility results for gram negative bacilli isolated from blood cultures on antimicrobial choices and early switches of antimicrobial therapy.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Ghent, 9000, Belgium
Sepsis and septic shock are defined as a (life-threatening) organ dysfunction caused by an (uncontrolled) host response to an infection. Sepsis remains a leading cause of morbidity and mortality worldwide. In addition, sepsis is also associated with prolonged hospitalization and additional healthcare costs.
Sepsis and septic shock can be caused by a bloodstream infection. If bloodstream infection is suspected, blood cultures are collected.
In recent years, various devices and methods have been developed to make an antibiogram possible after a few hours, instead of the next day. The Q-linea AStar system will be used for this purpose in the medical microbiology laboratory. In contrast to the classic method, blood from the blood culture is not grafted onto a growth medium, but this blood is placed in a specific cartridge on the device, after which automatic sample processing takes place, which after six hours leads to a definitive susceptibility result for a large number of gram-negative bacilli and causes of bloodstream infections. Moreover, the reported antibiogram is not based on disk diffusion but on 'broth' microdilution (ISO 2776-1) where the sensitivity to a specific antibiotic is determined on the basis of a dilution series. This method allows sensitivity to be reported not only qualitatively (sensitive or resistant), but also allows reporting of the minimum inhibitory concentration (MIC value). This is the lowest concentration of an antibiotic at which the growth of the bacteria is inhibited and this fact allows the dose administered to be optimized if necessary.
The aim of this study is therefore, if this new method can be implemented, to retrospectively determine whether making the antibiogram more quickly available in the epidemiological setting of Ghent University Hospital offers added value: does the early available information lead to necessary and beneficial antibiotherapy changes or does the traditional diagnosis with reporting one day later prove to be equivalent? If the new working method were to lead to a clinically significant improvement in the established policy, this could necessitate an organizational adjustment in the operation of the laboratory.
To gain insight into this, clinical data will be collected during the study period necessary to evaluate the extent to which the faster results have had an impact on the antibiotherapy. There is therefore no need for additional sample collection from the patient. All collected data result from the standard hemoculture taken due to fever and/or frissons and concern clinical data that is routinely collected to formulate antibiotic recommendations for patients with positive hemocultures.
The following data will be collected pseudonymised for samples processed according to the new best practice:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with blood culture positive with gram negative bacilli
-
Exclusion criteria
Rapid AST with ASTAR
Time frame: 24 hours
Time tot first effective antibiotic therapy
Time frame: 72 hours
Time to optimal antibiotic therapy
Time frame: 14 days
Number of different antibiotic classes used in treatment
Time frame: 14 days
Time to stop antibiotic therapy
Time frame: 72 hours
Time of empiric treatment
University Hospital, Ghent
Other
Acronym: RASTA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04821661
Bacteremia, Bacterial Infections
Brisbane, Queensland, Australia
View Trial DetailsNCT05184764
Bacteremia, Bacteremia Due to Staphylococcus Aureus
Tucson, Arizona, United States
View Trial DetailsNCT04478721
Bacteremia, Bacterial Infections
Sabadell, Barcelona, Spain
View Trial DetailsNCT05741424
Bacteremia, Bacterial Infections
Nîmes, France
View Trial Details